Nanologica AB (SE:NICA)
:NICA
Want to see SE:NICA full AI Analyst Report?
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.33 - kr2.25
Previous CloseN/A
Volume105.00
Average Volume (3M)111.94K
Market Cap
kr218.30M
Enterprise Valuekr138.73M
Total Cash (Recent Filing)kr39.25M
Total Debt (Recent Filing)kr119.07M
Price to Earnings (P/E)0.1
Beta1.31
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding328,769,840
10 Day Avg. Volume89,035
30 Day Avg. Volume111,941
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr83.10M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained TTM revenue growth (+50.7%) indicates accelerating commercial traction in pharmaceutical purification. Durable top-line momentum supports scaling manufacturing and recurring consumable sales, increasing the likelihood of achieving operating leverage as adoption broadens.
Proprietary TechnologyNanologica’s porous silica platform and chromatographic media target a specialized drug-purification niche. The technical differentiation and long development cycles in pharma create customer stickiness and high switching costs, supporting durable demand and structural competitive advantage.
Asset Base / EquityA sizeable asset base and positive equity (~262M in total assets) provide financial optionality to fund R&D, scale manufacturing or pursue partnerships. This stronger capital base gives resilience and strategic flexibility during growth, compared with asset-light startups.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow (~-26.9M and -27.9M TTM) forces reliance on external financing. Ongoing cash burn raises dilution and refinancing risk, constrains capital spending for capacity or R&D, and reduces resilience if revenue growth slows.
Unprofitable OperationsDeeply negative gross and operating profits show the core business isn't yet self-sustaining. Reported TTM net income appears influenced by non-operating items, so earnings quality is uncertain and margins must materially improve for durable profitability.
Rising LeverageDebt-to-equity rising to ~1.22 increases financial risk versus prior periods. Combined with cash burn and operating losses, higher leverage raises interest and covenant risk, narrows strategic flexibility and heightens sensitivity to capital market conditions.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.33 and its highest was kr2.25 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr218.30M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Aug 27, 2026 which is in 94 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on May 20, 2026. The company reported kr0.719 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.719.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of kr0.719 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 32.383%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―